News

Upperton Pharma Solutions Win’s Prestigious King’s Award for Enterprise: International Trade 2023

by
Upperton King's Award Presentation Photo

Upperton Pharma Solutions, a leading contract development and manufacturing organisation (CDMO) specialising in the development and manufacture of innovative drug formulations, has been announced as a winner of the King’s Award for Enterprise, International Trade. The King’s Award for Enterprise is a highly prestigious award for UK businesses who have demonstrated outstanding innovation in their industry. … Read more

Upperton Increases Oral Dosage Form Capabilities at its Nottingham HQ

by

20th April 2023 : Press Release Nottingham, UK, 20th April: Leading UK contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions (Upperton) has expanded its oral dosage form capabilities at its newly built headquarters in Nottingham, UK. Part of Upperton’s £15m investment program announced in January this year, the state-of-the-art facility has benefited from a … Read more

Seasons Greetings To All Of Our Customers

by

December 21st 2022 : Newsletter Traditionally at this time of year we like to offer Season’s Greetings to all our customers and friends and whilst doing so, look back over the years at some of the highlights in what has been an exceptionally busy (and successful) year for Upperton Pharma Solutions! Here are just a … Read more

Upperton Pharma Solutions Appoints T-SQUARED for Design and Build of New Development & Manufacturing Facility

by

29th November 2022 – Press Release & Newsletter Upperton Pharma Solutions Appoints T-SQUARED for Design and Build of New Development and Manufacturing Facility Upperton Pharma Solutions, a leading UK contract development and manufacturing organisation (CDMO), is delighted to announce that it has appointed T-SQUARED, UK based company, as the principal Design and Build contractor for … Read more

Upperton Launches ASAPprime® Shelf-Life Stability Testing

by

November 16th 2022 : Newsletter Upperton has made a significant investment in ASAPprime® software and hardware to enable the company to offer its clients state of the art stability testing. This exciting new platform can be used to generate robust, accelerated chemical stability data and is now being applied at all stages of the product … Read more

Inflexion announces investment into Upperton

by

21st April 2022 – Press Release Inflexion is pleased to announce it has made a substantial investment into Upperton Pharma Solutions (“Upperton”), a UK-based specialist contract development and manufacturing organisation (“CDMO”) which has expertise in particle engineering for the pharmaceutical industry. Inflexion has invested alongside the founder and the management team who will continue to … Read more

20th May 2021 – Upperton Nasal Delivery Article Published in ONdrugDelivery

by

Article 20th May 2021 – Upperton Nasal Delivery Article Published in ONdrugDelivery Formulation Options In Nasal Drug Delivery Upperton had an article published in Edition 119 ONdrugDeliver in May 2021 In the article Richard Johnson, CEO and founder of Upperton,  discusses the advantages of nasal delivery and why there is growing interest in this route … Read more

29th April 2021 – Formulation Options in Nasal Drug Delivery

by

News 29th April 2021 – Formulation Options in Nasal Drug Delivery Nasal delivery offers a number of unique opportunities for the successful delivery of drugs and vaccines either locally, systemically or directly to the central nervous system. This utility has resulted in growing interest from scientists looking to administer both therapeutic agents and vaccines via … Read more

Upperton Pharma Solutions is an early phase Pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with more than twenty years of experience in the development of pharmaceutical dosage forms.

Quick Links

Kings Award for Enterprise - Internal Trade 2023 Logo

Albert Einstein Centre, Nottingham Science Park, Nottingham, UK NG7 2TN,
Phone: +44 (0) 115 855 7050
Email: [email protected]